Therapeutic index of H1-antihistamines: Example of cetirizine

Annals of Allergy, Asthma and Immunology

Volumn 83, Issue 5, 1999, Pages 489-492

  Rihoux, J P ^a  

^a Pharma   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ASTEMIZOLE; CETIRIZINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVOCABASTINE; LORATADINE; OXATOMIDE; TERFENADINE;

ATOPIC DERMATITIS; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; IMMEDIATE TYPE HYPERSENSITIVITY; METABOLISM;

CETIRIZINE; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY, IMMEDIATE;

EID: 0032590001     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62856-6     Document Type: Article

References (33)

1. Hüther KJ, Renftle G, Barraud N, et al. Inhibitory activity of terfenadine on histamine-induced skin wheals in man. Eur J Clin Pharmacol 1977;12: 195-199.
2. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J 1989:298-325.
3. Hoppu K, Tikanoja T, Tapanainen P, et al. Accidental astemizole overdose in young children. Lancet 1991;338: 538-540.
4. Clark S. Dangers of non-sedating anti-histamines. Lancet (May) 1997;349, no9061:1268.
5. Fadel R, Herpin-Richard N, Rihoux JP, Henocq E. Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo. Clin Allergy 1987;17: 373-379.
6. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduced inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95:612-621.
7. Rédier H, Chanez P, De Vos C, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992;90:215-224.
8. Charlesworth EN, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989;83:905-912.
9. Okada C, Eda R, Miyagawa H, et al. Effect of cetirizine on human eosinophil superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro. Int Arch Allergy Immunol 1994;103:384-390.
10. Snyman JR, De Sommers K, Van Wyk M, Lizamore DJ. Effect of longterm cetirizine treatment on the cutaneous hypersensitivity reaction in patients with grass pollen allergy. Eur J Clin Pharmacol 1994;46:1-4.
11. Sehmi R, Walsh GM, Hartnell A, et al. Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro. Pediatr Allergy Immunol 1993;4(Suppl4):13-18.
12. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduced inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95:612-621.
13. Boone M, Renard N, Rihoux JP, et al. In press in B. J. Dermatol. Adhesion molecules profiles in the skin of atopic dermatitis and of allergic contact dermatitis before and after patch testing. Pharmacological modulation by cetirizine. Poster presented at European Contact Dermatitis congress in 1996.
14. Ciprandi G, Buscaglia S, Pesce G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol December 1995;6:971-972.
15. Fasce L, Ciprandi G, Pronzato C, et al. Cetirizine reduces ICAM-1 on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol 1996;109: 272-276.
16. Caproni M, Palleschi GM, Falcos D, et al. Pharmacologic modulation by cetirizine of some adhesion molecules expression in psoriatic skin lesions. Int J Dermatol 1995/7, 34/7:510-513.
17. 1 antagonist cetirizine inhibits IL-8 release from human neutrophils induced by the respiratory-syncytial-virus. Submitted for publication.
18. Schute J. Interleukin 8 is a potent eosinophil chemo-attractant. Clin Exp Allergy 1994;24:203-206.
19. Louis R, Shute J, Biagi S, et al. Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum. Am J Respir Crit Care Med 1997;155:466-472.
20. Michiels M, Van peer A, Woestenborghs R, Heykants J. Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 1986; 8:53-62.
21. Matzke GR, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol 1990;3: 364-371.
22. Fisher MJE, Paulussen JJC, Roozendaal R, et al. Relation between effects of a set of anti-allergic drugs on calcium pathways and membrane structure in Fc∈RI activated signal transduction. Inflamm Res 1996;45: 564-573.
23. Weinschenck HP, Ziegler A. Terfenadine, surface activity and kinetic of action. Arch Pharmacol 1993; 347(Suppl):R44-173.
24. Kodavanti U, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 1990;42(4):327-354.
25. 1) antagonists.
26. Tillement JP, Albengres E. Peut-on adapter la distribution d'un médicament dans l'organisme aux localisations de ses cibles. L'exemple des antihistaminiques et de la cetirizine. Allergie Immunol 1996;28(10): 330-332.
27. 1-receptor antagonist. In press in J of Medicinal Chemistry.
28. Köller M, Hilger RA, Rihoux J-P, König W. Cetirizine exerts antiinflammatory effects on human neutrophils. Int Arch Allergy Immunol 1996;110:52-56.
29. Rihoux JP, Masliah J, Bereziat G, König W. G-proteins as biological targets for antiallergic drugs. Int Arch Allergy Immunol 1997;113:339-341.
30. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987;59(Part II):4-8.
31. Detert H, Seifert R, Schunack W. Cationic amphiphiles with G-protein stimulatory activity: studies on the role of the basic domain in the activation process. Pharmazie 1996;51:67-72.
32. Chalon P, Vita N, Kaghad M, et al. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 1996;386:91-94.
33. Lindquist M, Edwards R. Risks of non sedating antihistamines. Lancet 1997; 349, May 3.